IGC Pharma, Inc. (IGC) Stock

IGC Pharma, Inc. (IGC) is a Healthcare stock trading at $0.30 (as of 2026-08-21), with a market capitalization of $31.49M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

IGC Pharma, Inc. is a clinical-stage pharmaceutical company focused on developing investigational therapies for Alzheimer’s disease, including IGC-AD1 for agitation in dementia due to Alzheimer’s (Phase 2) and TGR-63 (pre-clinical). The company also works on applying AI to Alzheimer’s research and is headquartered in Potomac, Maryland.

Understand IGC Pharma, Inc.: how it makes money

IGC Pharma is a clinical-stage pharmaceutical company developing investigational Alzheimer treatments, with IGC-AD1 in a Phase 2 trial for agitation in dementia due to Alzheimer's and TGR-63 in pre-clinical development, and it currently shows 0.0 reported revenue in the latest quarter.

Because the company has 0.0 reported revenue in the latest quarter, its near-term profit and loss profile is driven primarily by development-stage progress across IGC-AD1 (Phase 2) and TGR-63 (pre-clinical), rather than by product sales.

Business quality (Weak): The business is clearly focused on Alzheimer drug development (two investigational assets, one in Phase 2). The main transparency issue for retail investors is that, based on the latest quarter shown, there is no reported revenue, so operating results reflect the R&D stage and milestone execution rather than sales performance.

Bull case

  • Pipeline clarity in Alzheimer disease: The company has two investigational Alzheimer-focused assets, IGC-AD1 (Phase 2) for agitation in dementia due to Alzheimer's and TGR-63 (pre-clinical) in development.
  • Advancing programs through clinical and pre-clinical stages: IGC-AD1 is already in Phase 2, which is a more advanced stage than TGR-63's pre-clinical status.

Bear case

  • No reported revenue in the latest quarter: For the period ended 2026-03-31, reported revenue is 0.0, so the company is not yet demonstrating monetization from any products.
  • Very large operating losses: The latest-quarter operating margin is -775.4, indicating substantial operating loss relative to revenue.
  • Clinical-stage uncertainty: One asset is in Phase 2 (IGC-AD1) and another is pre-clinical (TGR-63), and both stages carry the risk that results may not support continued advancement.
Valuation — source: SEC EDGAR (first-party)
Price$0.30
Market Cap$31.49M
Price / Book5.14
Price / Sales28.60
FCF Yield-27.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$869000.00
Net Margin-477.1%
Revenue Growth (YoY)-19.2%
EPS Growth (YoY)50.0%
FCF Growth (YoY)82.3%
Financial Health — source: SEC EDGAR
Altman Z-Score-12.70 (distress)
Piotroski F-Score2/9 (weak)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($322945.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORam Mukunda
Employees67
CountryUS
IPO Date2006-05-24

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Lite Strategy, Inc. (LITS)
  • MIRA Pharmaceuticals, Inc. (MIRA)
  • Actuate Therapeutics Inc (ACTU)
  • Lantern Pharma Inc. (LTRN)
  • Daré Bioscience, Inc. (DARE)
  • BeyondSpring Inc. (BYSI)
  • NextCure, Inc. (NXTC)
  • NanoViricides, Inc. (NNVC)
IGC earnings history · IGC institutional & insider holders · IGC KPIs & operating metrics · IGC financials · IGC investor presentations & press releases · IGC SEC filings · IGC peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.